Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=180 Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients
Postoperative Nausea and Vomiting
Primary: Incidence of Postoperative Nausea and Vomiting — 34.4; 29.8; 12.5; 7 percentage of participants — p=>0.76
N/A N=300 Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Cancer · Nausea · Vomiting
Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants
Phase 3 N=317 Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Breast Carcinoma
Primary: Average Nausea Defined as the Average [ MAXIMUM ] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or…
Phase 2 N=189 Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Radiotherapy-induced Nausea and Vomiting (RINV)
Primary: Complete Control (no Signs of Emesis or Moderate to Severe Nausea and no Use of Rescue Medication) Rate From the Start of Radiotherapy Until 24 Hours After the Third…
Phase 2 N=85 Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Chemotherapy-Induced Nausea and Vomiting · Ovarian Cancer
Primary: Efficacy of the Aprepitant/Ramosetron/Dexamethasone Regimen in Terms of the Proportion of Patients With a Complete Response (CR) During the 120 Hour Following Initiation…
Phase 3 N=1,021 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
Nausea
Primary: Home Record: Severity of Delayed Nausea — 1.88; 1.65; 1.87; 1.68 units on a scale — p=0.718
Phase 3 N=80 Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy
Vomiting · Cisplatin Adverse Reaction
Primary: Number of Patients With Complete Response During Chemotherapy Course 1 — 17; 26 participants — p=0.04
N/A N=9 Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Patients With Gastroparesis Who Have Failed Standard Therapy
Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants
Phase 2 N=64 Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
Nausea and Vomiting
Primary: Vomiting at 0 to 120 Min. — 1; 4 number of participants exp vomiting
Phase 2 N=68 Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Control — 71.4; 76.0; 90.9 Percentage
N/A N=49 Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
Phase 2 N=342 Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
CINV
Primary: Number of Participants With Delayed Phase Complete Response(CR) — 37; 13; 27; 21 Participants — p=0.004
N/A N=200 Aprepitant for Post-operative Nausea
Postoperative Nausea
Primary: Post-operative Nausea and Vomiting
N/A N=115 Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
Nausea · Vomiting
Primary: Number of Participants With Postoperative Nausea and Vomiting — 28; 34 participants
Phase 2 N=126 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
Gastroparesis
Primary: Number of Participants With Improvement in Nausea — 29; 25 participants — p=0.43
Phase 3 N=30 Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
Advanced Cancer
Primary: Mean Nausea Scores — 1; 9 units on a scale
N/A N=115 Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
Nausea · Vomiting
Primary: Number of Participants With Nausea and Vomiting — 24; 29 participants
Phase 3 N=848 Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
Chemotherapy-Induced Nausea and Vomiting
Primary: Number of Patients Who Reported No Vomiting — 324; 252 Participants — p=<0.01
Phase 3 N=380 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Hematopoietic/Lymphoid Cancer · Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants
N/A N=84 Guanfacine for PONV and Pain After Sinus Surgery
Postoperative Nausea and Vomiting · Pain, Postoperative
Primary: Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) — 35; 33; 1; 2 Participants
Phase 2 N=136 Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Nausea · Vomiting · Glioma
Primary: Proportion of Patients Achieving Complete Control (CC) — 0.59; 0.55 proportion of patients
Phase 3 N=1,455 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1 — 76.9; 69.5 percentage of responders — p=0.001
Phase 3 N=413 A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Adverse Events — 86.0; 91.3 percentage of patients with TEAE
Phase 3 N=120 Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
Chemotherapy-induced Nausea and Vomiting
Primary: Proportion of Participants Receiving HEC With Complete Response in Overall Phase — 20; 15 Participants — p=0.397
Phase 3 N=69 Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Germ Cell Tumors
Primary: Complete Response. — 47; 15 percentage of evaluable subjects
Phase 2 N=144 Olanzapine for Nausea After Surgery
Postoperative Nausea and Vomiting
Primary: Number of Participants With Nausea and/or Vomiting — 10; 26 Participants — p=0.003
N/A N=27,034 Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
Postoperative Nausea and Vomiting
Primary: Adherence to PONV Guidelines — 666; 5260; 5863 Participants
Phase 3 N=710 A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
Nausea and Vomiting, Chemotherapy-Induced
Primary: Percentage of Participants Who Achieved a Complete Response in the Overall Phase (0-120 Hours) Following Initiation of the First Cycle of an Oxaliplatin Based Moderately…
Phase 3 N=280 The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy
Nausea and Vomiting of Pregnancy
Primary: Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall…